'Estradiol' http://www.hormone-facts.com/estradiol/ 2008-11-21T13:15:22+01:00 text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#new-study-data:-januvia--significantly-reduced-blood-sugar-levels-and-was-not-associated-with-... NATIONAL HARBOR, Md.----New data presented at the 61st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA™ , a diabetes medicine from Merck & Co., Inc., significantly reduced blood sugar levels in elderly patients with type 2 diabetes and was not associated with hypoglycemia . text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#jci-table-of-contents:-nov.-20,-2008 ( Journal of Clinical Investigation ) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published Nov. 20, 2008, in the JCI: "Preventing tumor cells from refueling: a new anti-cancer approach?"; "To contract or not: a key question for the uterine muscles in pregnancy"; "Helping the embryo implant: a new role for one type of immune ... text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#innovative-birth-control-method:-a-low-dose,-once-weekly-contraceptive-patch,-phase-3-trials Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's health products, announced today that after a successful end-of-Phase 2 meeting with the Food and Drug Administration (FDA), the company is moving forward with its pivotal Phase 3 program to support a NDA filing and marketing approval of AG200-15 with SKINFUSION™ technology. text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#agile's-lead-product,-ag200-15,-moving-into-pivotal-phase-3-trials Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's health products, announced today that after a successful end-of-Phase 2 meeting with the Food and Drug Administration, the company is moving forward with its pivotal Phase 3 program to support a NDA filing and marketing approval of AG200-15 with SKINFUSION(TM) technology. AG200-15 is an innovative, low-dose ... text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#researchers-tackle-cll,-diabetes-and-trauma-hemorrhage---molecular-medicine,-a-bi-monthly-journal Chronic Lymphocytic Leukemia (CLL) is a disease of the B lymphocytes of the immune system. Under normal conditions, B lymphocytes (or B cells) play an important role in battling infection. CLL is a disease manifested by uncontrolled growth of these B lymphocytes. text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#biosante-pharmaceuticals-announces-receipt-of-nih-grant-for-inhaled-interferon LINCOLNSHIRE, Ill.----BioSante Pharmaceuticals, Inc. announced today that the company has been awarded a $150,000 Small Business Innovation Research grant from the National Institutes of Health to support the company's development of formulations for the pulmonary delivery of interferon alpha using its proprietary calcium phosphate nanoparticulate technology. text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#researchers-tackle-cll,-diabetes-and-trauma-hemorrhage Molecular Medicine, a bimonthly, biomedical journal published by The Feinstein Institute for Medical Research, strives to understand normal body functioning and disease pathogenesis at the molecular level which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. Featured in ... text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#testosterone-effective-in-female-sexual-dysfunction;-biosante-conducting-long-term-safety-study-of-libigel-in-fsd BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male hypogonadism, commented today on a new publication reporting on the efficacy of testosterone in the treatment of Female Sexual Dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD) in menopausal women. text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#sex-hormones-may-influence-hardening-of-arteries Washington, November 12 : Johns Hopkins researchers say that naturally produced sex hormones may influence the risk and progression of atherosclerosis, commonly referred to as the hardening of the arteries. text/html http://www.hormone-facts.com/endocrine-hormone-news/estradiol/#sex-hormones-may-affect-atherosclerosis Naturally produced sex hormones may influence the risk and progression of atherosclerosis, or hardening of the arteries, Johns Hopkins researchers report in a recent study.